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Figure 1. OP1 activates canonical (P-Smad 1/5/8 signaling in A) healthy
and B) OA meniscus cells. C) P-Smad 1/5/8 densitometry, normalized to b-
actin, relative to unstimulated controls (mean þ/- SD).
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S18cartilage degeneration. Knee joints from the mice at 4 and 8 weeks post
surgery (n¼4 in each group) were collected for morphological analysis.
Results: 1) We did not ﬁnd the initiation and acceleration of articular
cartilage degeneration by the genetic inactivation of Tgfbr2 in knee
joints of mice at the age of 9 months or older. We also did not ﬁnd
hypertrophic chondrocytes in the articular cartilage of the mice. 2) We
found that intra-articular injection of neutralizing TGF-b1 antibody into
the knee joints of Col11a1þ/- mice delayed articular cartilage degen-
eration approximately 3 months, compared to that in Col11a1þ/- mice
without the injection of the antibody. It takes about 15 months for
Col11a1þ/- mice to form OA knee joints. 3) We found that treatment
with Losartan delayed articular cartilage degeneration, induced by
DMM, compared to that in control littermates. 4) We found that
removal of Tgfbr2 in articular cartilage of knee joints delayed articular
cartilage degeneration, induced by DMM, at least 6 weeks, compared to
that in wild-type littermates. It takes about 16 weeks for mice with
DMM to develop OA knee joints.
Conclusion: Inhibition of Tgf-b1 signaling attenuated articular cartilage
degeneration in mature knee joints of mouse models of OA. Therefore,
inhibition activity of TGF-b1, not application of TGF-b1, may be con-
sidered in treatment of OA in mature joints.
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Purpose: Degenerative meniscus injuries are highly prevalent in aged
individuals, increasing the risk and rate of total joint OA onset. Ideally,
therapies should incite anabolic matrix production and prevent total
joint tissue OA progression. However, anabolic resistance occurs during
articular cartilage aging and OA. It is thought to contribute to the risk of
OA progression due to insufﬁcient repair of normal tissue microtrauma.
Anabolic insensitivity also contributes to net tissue breakdown during
OA due to decreased tissue synthesis. Mechanisms of anabolic insen-
sitivity have not been described for meniscus tissue. The objective of
this study was to characterize normal and OA meniscus cell response to
the anabolic growth factor, Osteogenic Protein 1 (OP1/BMP7), and
examine mechanisms of anabolic resistance to OP1 during OA.
Methods: Normal human tissue was obtained through NDRI or Gift of
Hope Tissue and Organ Donor Network. Osteoarthritic tissues were
obtained as total knee arthroplasty surgical waste under IRB approval.
Normal meniscus was grade 2 or less by ICRS scores. Primary meniscus
cells were grown as high density monolayer cultures, changed to serum
free media upon reaching conﬂuence, and treated with OP1 (100 ng/
mL) or comparisons of IL1b (10 ng/mL), TGFb (10 ng/mL), GDF5 (100 ng/
mL), or IGF1 (100 ng/mL). Expression of ECM components and MMPs
was determined by RT-qPCR. Total lysates were analyzed by immuno-
blotting and evaluated using antibodies against activating phosphor-
ylations or total proteins for Smads (1/5/8, 2), MAPKs (ERK, p38), and
AKT. Band intensity was measured by ImageJ densitometry, normalized
for background and total protein, and expressed relative to unstimu-
lated samples.
Results: By RT-qPCR, OP1 stimulation increased aggrecan and collagen
type II (COL2A1) mRNA and decreased MMP-13 mRNA in all samples,
however OA meniscus cells showed reduced responses compared to
healthy cells. Normal meniscus cells separated from inner and outer
meniscus regions displayed similar mRNA levels upon OP1 stimulation,
suggesting the decreased response of OA cells to OP1 was due to disease
state, not loss of tissue region (data not shown). To identify potential
mechanisms of anabolic insensitivity, we evaluated signaling time
courses by immunoblot. Normal (n¼2) and OA (n¼3) meniscus cells,
stimulated with OP1, displayed activation of canonical BMP signaling,
evidenced by Smad1/5/8 phosphorylation (P-Smad1/5/8), while non-
canonical MAPK or AKT signaling was not observed (Figure 1A&B).
Maximum P-Smad1/5/8 occured at late time points (1.5 hours) with
similar kinetics between normal and OA cells. Normal cells responded
to OP1 stimulation with enhanced levels of P-Smad1/5/8 compared to
OA cells (Figure 1C). Stimulation with IL-1b or IGF1 showed limited
Smad 1/5/8 activation, while MAPK or AKT was activated, as expected.
Stimulation with TFGb resulted in both enhanced phospho-Smad 2 and
Smad 1/5/8 in normal and OA cells compared to unstimulated controls.
TFGb treatment induced higher phospho-Smad 1/5/8 levels in normal
vs. OA meniscus cells, similar to OP1 treated cells.Conclusions: OA meniscus cells are resistant to OP1 stimulated
extracellular matrix transcription compared to normal meniscus cells.
MMP expression is not induced by either normal or OA meniscus cells,
indicating that OP1 is not harmful and has potential therapeutic beneﬁt
for OA meniscus. Both normal and OA meniscus cells respond to OP1
stimulation by activating canonical BMP signaling (Smad1/5/8), but not
non-canonical signaling. Our current signaling experiments using OP1
and including TFGb suggest that meniscus anabolic resistance does not
affect kinetics of Smad activation, but inﬂuences total amount of Smad
phosphorylation. Stimulation with TFGb also resulted in differential
Smad 1/5/8 activation, suggesting that Smad signaling is a target
pathway for overcoming anabolic resistance during meniscus cell OA.
Discovering mechanisms of OA cell anabolic resistance will enhance
therapeutic targeting to overcome resistance and contribute to resto-
ration of tissue homeostasis beneﬁcial to the whole knee joint.23
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Purpose: Despite the advantages in the ﬁeld of regenerative medicine
for cartilage repair, the research of available and effective treatments for
osteoarthritis (OA) represents a major challenge for clinicians. To this
regard, the use of bone marrow concentrate (BMC), containing different
cell populations including Mesenchymal Stromal Cells (MSCs) sur-
rounded by their microenvironment with a cocktail of multiple growth
factors, could represent a novel therapeutic approach for OA manage-
ment. This methodology allows to perform a one -step procedure
through a density gradient centrifugation of autologous bone marrow
avoiding all the problems related to cell manipulation. Most recent
studies demonstrated beneﬁts of the use of BMC for osteochondral
reconstruction in critical-sized defects.The purpose of this study was,
therefore, to assess the efﬁcacy of the use of BMC seeded onto a hya-
luronan scaffold compared to the use of expanded isolated MSCs in a
sheep model of OA.
Methods: Skeletally mature female Merino sheep were used for this
study.The induction of OAwas done surgically through unilateral partial
medial meniscectomy (MMX) to achieve amild grade of OA at 12weeks.
Treatment approaches consisted of autologous BMC and/or MSC seeded
onto Hyaff-11 from bone marrow and transplanted into the knee joint;
no treatment (OA group) and empty Hyaff-11 were used as controls.
Cartilage from femoral condyle and tibial plateau, synovial membranes
and medial menisci were assessed by macroscopic and histological
analysis supplemented by speciﬁc scoring systems. Protein expression
of various ﬁbrous, cartilaginous, catabolic, hypertrophic and inﬂam-
matory markers were examined by immunohistochemistry. All the
assessments were carried out 3 months after implantation. Data were
reported using 95% conﬁdence of interval of the mean and/or mean
with standard deviation.
Results: A mild grade of OA was developed after MMX at 12 weeks. A
series of OA changes, including cartilage loss, cell clones, hypertrophic
processes, subchondral bone thickness, osteophytes, hyperplasia of
